Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Tomaszuk

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
PRRT as neoadjuvant treatment in NETAnna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Monika Tomaszuk
European Journal of Nuclear Medicine and Molecular Imaging|May 31, 2012
Comment on Pepe et al.: somatostatin receptor SPECTAlicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Monika Tomaszuk
Radiation Protection Dosimetry|January 30, 2016
EYE LENS DOSES IN NUCLEAR MEDICINE: A MULTICENTRIC STUDY IN BELGIUM AND POLANDJérémie Dabin, Renata Kopeć, Lara Struelens, et al.
Nuclear Medicine Review. Central & Eastern Europe|May 17, 2013
Optimization of image reconstruction method for SPECT studies performed using [⁹⁹mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumorsAnna Sowa-Staszczak, Wioletta Lenda-Tracz, Monika Tomaszuk, et al.
Przeglad Lekarski|August 7, 2010
[Fusion SPECT/CT in clinical practice]Anna Sowa-Staszczak, Robert Chrzan, Monika Tomaszuk, et al.
Nuclear Medicine Review. Central & Eastern Europe|May 21, 2011
Biokinetics of ¹³¹I after endogenous and exogenous stimulation of TSH in patients with DTCMonika Buziak-Bereza, Monika Tomaszuk, Dorota Pach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 12, 2011
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, et al.
Clinical Imaging|June 26, 2012
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?Anna Sowa-Staszczak, Robert Chrzan, Dorota Pach, et al.
Nuclear Medicine Review. Central & Eastern Europe|January 6, 2012
Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefańska, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 3, 2011
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NETDorota Pach, Anna Sowa-Staszczak, Jolanta Kunikowska, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
PRRT as neoadjuvant treatment in NETAnna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Monika Tomaszuk
European Journal of Nuclear Medicine and Molecular Imaging|May 31, 2012
Comment on Pepe et al.: somatostatin receptor SPECTAlicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Monika Tomaszuk
Radiation Protection Dosimetry|January 30, 2016
EYE LENS DOSES IN NUCLEAR MEDICINE: A MULTICENTRIC STUDY IN BELGIUM AND POLANDJérémie Dabin, Renata Kopeć, Lara Struelens, et al.
Nuclear Medicine Review. Central & Eastern Europe|May 17, 2013
Optimization of image reconstruction method for SPECT studies performed using [⁹⁹mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumorsAnna Sowa-Staszczak, Wioletta Lenda-Tracz, Monika Tomaszuk, et al.
Przeglad Lekarski|August 7, 2010
[Fusion SPECT/CT in clinical practice]Anna Sowa-Staszczak, Robert Chrzan, Monika Tomaszuk, et al.
Nuclear Medicine Review. Central & Eastern Europe|May 21, 2011
Biokinetics of ¹³¹I after endogenous and exogenous stimulation of TSH in patients with DTCMonika Buziak-Bereza, Monika Tomaszuk, Dorota Pach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 12, 2011
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, et al.
Clinical Imaging|June 26, 2012
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?Anna Sowa-Staszczak, Robert Chrzan, Dorota Pach, et al.
Nuclear Medicine Review. Central & Eastern Europe|January 6, 2012
Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?Anna Sowa-Staszczak, Dorota Pach, Agnieszka Stefańska, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 3, 2011
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NETDorota Pach, Anna Sowa-Staszczak, Jolanta Kunikowska, et al.
Pageof 2